Jalra

Vildagliptin, the active ingredient in Jalra, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control when used with diet and exercise. GNH USA supplies Jalra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jalra, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus and related therapeutic pathways. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combination therapy): provides additional HbA1c reduction when added to metformin or sulfonylureas. - Type 2 diabetes mellitus (inadequately controlled): helps achieve target glycaemic goals alongside diet and exercise.

Vildagliptin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Headache: occasional tension‑type headache. - Dizziness: transient light‑headedness, especially on standing. - Upper respiratory tract infection: mild cold‑like symptoms. - Abdominal pain: intermittent discomfort in the abdomen. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting, requiring immediate medical attention. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Bullous skin reactions: blistering skin conditions. - Severe hypoglycaemia: prolonged loss of consciousness or seizures.

Before initiating therapy with Jalra, several safety considerations should be reviewed. - Renal impairment: adjust dose or avoid use in severe renal dysfunction. - Hepatic impairment: monitor liver function tests regularly. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia, monitor glucose closely. - History of pancreatitis: avoid use due to potential recurrence. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Vildagliptin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Insulin or sulfonylureas: may cause severe hypoglycaemia. - Strong CYP450 inhibitors (e.g., ketoconazole): can increase vildagliptin plasma levels. - GLP‑1 receptor agonists: additive incretin effect may increase risk of gastrointestinal symptoms.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose control, monitor blood sugar. - Rifampin: may reduce vildagliptin exposure, consider dose adjustment. - ACE inhibitors: monitor renal function when combined.